Drugs / HS628
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06048224 | Dec 2020 → Sep 2021 | rheumatoid arthritis | Zhejiang Hisun Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS628 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06048224 ↗ |
| Action | Inhibit | “Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection” NCT06048224 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection” NCT06048224 ↗ |
| Route | Subcutaneous | “HS628 SC injections Q4W along with MTX orally for 24-week” NCT06048224 ↗ |